Streetbeat News

Analyst Ratings

QRVO

Qorvo, Inc. (NASDAQ:QRVO) exceeded Q4 earnings and sales expectations but provided a weaker forecast for the next quarter, leading to a 4.2% drop in its shares. The company anticipates lower revenue and adjusted earnings for Q1 compared to analyst estimates. Following this, Needham, Mizuho, and Susquehanna adjusted their price targets on Qorvo, reflecting a cautious outlook.

Portfolio Pulse from Avi Kapoor

May 02, 2024 | 1:05 pm

TGTX

Ladenburg Thalmann analyst Matthew Kaplan has maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) and increased the price target from $39 to $40.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 1:04 pm

BTCUSD

DOGEUSD

ETHUSD

PEPEUSD

Cryptocurrency analyst DonAlt shared his views on Bitcoin's current state, suggesting a bullish outlook if it closes above $60,000 weekly. He expressed interest in investing in Ethereum, Dogecoin, and potentially Pepe if Bitcoin shows signs of bottoming. DonAlt's strategy focuses on trading opportunities rather than long-term investment in the crypto market.

Portfolio Pulse from Khyathi Dalal

May 02, 2024 | 1:03 pm

DASH

Wedbush analyst Scott Devitt reiterated a Neutral rating on DoorDash (NASDAQ:DASH) and maintained a $115 price target.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 1:02 pm

SSTK

Recent analyst ratings for Shutterstock (NYSE:SSTK) show a predominantly bullish outlook, with 5 bullish and 1 indifferent rating over the past three months. The average 12-month price target is $60.83, down from a previous $85.00, indicating a significant adjustment in expectations. Analysts from firms including Needham, Truist Securities, and Morgan Stanley have maintained or adjusted their ratings and price targets, reflecting varied perspectives on Shutterstock's market position and financial health. The company faces challenges in revenue growth, net margin, ROE, and ROA, but maintains a sound debt management profile.

Portfolio Pulse from Benzinga Insights

May 02, 2024 | 1:01 pm

GTES

Gates Industrial Corp (NYSE:GTES) has received mixed analyst ratings over the past three months, with a shift towards more bullish sentiments in the last 30 days. The average 12-month price target for GTES has increased by 13.76% to $19.1, with a high estimate of $26.00 and a low of $14.00. Analysts from firms including Baird, Goldman Sachs, Citigroup, Keybanc, Barclays, Wolfe Research, Jefferies, and Evercore ISI Group have updated their ratings and price targets, reflecting optimism about the company's future performance despite its recent challenges in revenue growth, net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

May 02, 2024 | 1:00 pm

CVS

Analyst ratings for CVS Health (NYSE:CVS) show a mix of bullish to bearish sentiments, with a recent shift towards more bullish ratings. The average 12-month price target is now $79.18, down from $87.00. Analyst actions include adjustments to ratings and price targets, reflecting dynamic market conditions and CVS Health's performance. CVS Health's financial indicators such as market capitalization, revenue growth, net margin, ROE, ROA, and debt management are highlighted, showcasing its strong market presence and financial health.

Portfolio Pulse from Benzinga Insights

May 02, 2024 | 1:00 pm

UTHR

United Therapeutics (NASDAQ:UTHR) has been the subject of diverse analyst ratings over the last three months, with a recent shift towards more bullish sentiments. The average 12-month price target for UTHR has risen to $311.14, marking a 4.06% increase from the previous target. The company, specializing in pulmonary arterial hypertension treatments, has shown a notable revenue growth of 25.07% over the past 3 months but faces challenges in net margin, ROE, and ROA compared to industry averages. Despite these challenges, its debt management is sound, with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 02, 2024 | 1:00 pm

OB

Outbrain (NASDAQ:OB) received mixed ratings from 4 analysts, with an average 12-month price target of $5.25, down from $7.25. The company faces a negative revenue trend with a -3.77% growth, but excels in net margin (7.51%), ROE (8.45%), and ROA (2.88%). Its debt-to-equity ratio is high at 0.59, indicating potential financial challenges.

Portfolio Pulse from Benzinga Insights

May 02, 2024 | 1:00 pm

CVNA

Wedbush analyst Seth Basham maintains a Neutral rating on Carvana (CVNA) and raises the price target from $80 to $120.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 1:00 pm